Figures & data
Scheme 1. (A) Preparation of Fe3O4/DOX/PLGA-PEG nanoparticles via the emulsion solvent evaporation method. (B) A schematic illustration for Fe3O4/DOX/PLGA-PEG nanocarriers system and then Dox release from nanocarriers to kill tumour cells with a dual function of the early diagnosis and the treatment of the tumours.
![Scheme 1. (A) Preparation of Fe3O4/DOX/PLGA-PEG nanoparticles via the emulsion solvent evaporation method. (B) A schematic illustration for Fe3O4/DOX/PLGA-PEG nanocarriers system and then Dox release from nanocarriers to kill tumour cells with a dual function of the early diagnosis and the treatment of the tumours.](/cms/asset/9b5eabdb-6297-4291-9f8e-1897d4222def/ianb_a_1687500_sch0001_c.jpg)
Figure 1. (A) FT-IR spectra of Fe3O4、DOX、PLGA-PEG and Fe3O4/DOX/PLGA-PEG. (B) 1HNMR spectra of PLGA-PEG and characterization of Fe3O4 and Fe3O4/DOX/PLGA-PEG nanocomposites. TEM image of (C) Fe3O4 and (D) Fe3O4/DOX/PLGA-PEG, Particle size distribution of (E) Fe3O4 and (F) Fe3O4/DOX/PLGA-PEG.
![Figure 1. (A) FT-IR spectra of Fe3O4、DOX、PLGA-PEG and Fe3O4/DOX/PLGA-PEG. (B) 1HNMR spectra of PLGA-PEG and characterization of Fe3O4 and Fe3O4/DOX/PLGA-PEG nanocomposites. TEM image of (C) Fe3O4 and (D) Fe3O4/DOX/PLGA-PEG, Particle size distribution of (E) Fe3O4 and (F) Fe3O4/DOX/PLGA-PEG.](/cms/asset/44c55dba-85dd-4e71-b584-696f11a0fa0b/ianb_a_1687500_f0001_c.jpg)
Figure 2. (A) Thermogravimetric chart of PLGA-PEG and Fe3O4/DOX/PLGA-PEG. (B) Cumulative DOX release profiles from Fe3O4/DOX/PLGA-PEG under 37 °C and the standard curve of DOX. (C) Cell viabilities of on 3T3 cells after incubation of various concentrations of PLGA-PEG nanocomposites for 24 h, as determined by the typical CCK-8 assay.
![Figure 2. (A) Thermogravimetric chart of PLGA-PEG and Fe3O4/DOX/PLGA-PEG. (B) Cumulative DOX release profiles from Fe3O4/DOX/PLGA-PEG under 37 °C and the standard curve of DOX. (C) Cell viabilities of on 3T3 cells after incubation of various concentrations of PLGA-PEG nanocomposites for 24 h, as determined by the typical CCK-8 assay.](/cms/asset/40fb8261-d527-4a4a-8271-e7589dfa05c8/ianb_a_1687500_f0002_c.jpg)
Figure 4. (A) MRI image of different concentrations of Fe3O4 nanoparticles. (B) R2 and R2* relaxometry rates of different concentrations of Fe3O4 nanoparticles.
![Figure 4. (A) MRI image of different concentrations of Fe3O4 nanoparticles. (B) R2 and R2* relaxometry rates of different concentrations of Fe3O4 nanoparticles.](/cms/asset/f244e69c-944f-46de-87f2-c659e6468387/ianb_a_1687500_f0004_c.jpg)
Figure 5. (A) MRI image of different concentrations of Fe3O4/DOX/PLGA-PEG. (B) R2 and R2* relaxometry rates of different concentrations of Fe3O4/DOX/PLGA-PEG nanoparticles.
![Figure 5. (A) MRI image of different concentrations of Fe3O4/DOX/PLGA-PEG. (B) R2 and R2* relaxometry rates of different concentrations of Fe3O4/DOX/PLGA-PEG nanoparticles.](/cms/asset/5fe8302e-69ac-41a7-b6ca-bcf9eb8b547f/ianb_a_1687500_f0005_c.jpg)